Lower leptin/adiponectin ratio and risk of rapid lung function decline in chronic obstructive pulmonary disease

Annals of the American Thoracic Society

Volumn 11, Issue 10, 2014, Pages 1511-1519

  Suzuki, Masaru ^a   Makita, Hironi ^a   Östling, Jörgen ^b   Thomsen, Laura H ^c   Konno, Satoshi ^a   Nagai, Katsura ^a   Shimizu, Kaoruko ^a   Pedersen, Jesper H ^c   Ashraf, Haseem ^c,d   Bruijnzeel, Piet L B ^b   Maciewicz, Rose A ^b   Nishimura, Masaharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b ASTRAZENECA R AND D   (Sweden)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adipokines; Biological markers; Cohort studies

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; LEPTIN;

AGED; AIRFLOW; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPOTHESIS; INFLAMMATORY DISEASE; JAPANESE (PEOPLE); LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; RISK ASSESSMENT; BLOOD; CLINICAL TRIAL; DISEASE COURSE; FOLLOW UP; MULTICENTER STUDY; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ADIPONECTIN; AGED; BIOLOGICAL MARKERS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; LEPTIN; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84920402288     PISSN: 23296933     EISSN: 23256621     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201408-351OC     Document Type: Article

References (32)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease updated 2014; 2014 [updated 2014 Jan 23; accessed 2014 May 14]. Available from: Www.goldcopd.org.
2. Nishimura M, Makita H, Nagai K, Konno S, Nasuhara Y, Hasegawa M, Shimizu K, Betsuyaku T, Ito YM, Fuke S, et al.; Hokkaido COPD Cohort Study Investigators. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:44-52.
3. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, et al.; ECLIPSE Investigators. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011;365:1184-1192.
4. Casanova C, de Torres JP, Aguirre-Jaíme A, Pinto-Plata V, Marin JM, Cordoba E, Baz R, Cote C, Celli BR. The progression of chronic obstructive pulmonary disease is heterogeneous: The experience of the BODE cohort. Am J Respir Crit Care Med 2011;184:1015-1021.
5. Park HY, Churg A, Wright JL, Li Y, Tam S, Man SF, Tashkin D, Wise RA, Connett JE, Sin DD. Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:1413-1419.
6. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97.
7. Tomoda K, Yoshikawa M, Itoh T, Tamaki S, Fukuoka A, Komeda K, Kimura H. Elevated circulating plasma adiponectin in underweight patients with COPD. Chest 2007;132:135-140.
8. Chan KH, Yeung SC, Yao TJ, Ip MS, Cheung AH, Chan-Yeung MM, Mak JC; COPD Study Group of the Hong Kong Thoracic Society. Elevated plasma adiponectin levels in patients with chronic obstructive pulmonary disease. Int J Tuberc Lung Dis 2010;14: 1193-1200.
9. Kirdar S, Serter M, Ceylan E, Sener AG, Kavak T, Karadaʇ F. Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease. Scand J Clin Lab Invest 2009;69: 219-224.
10. Carolan BJ, Kim YI, Williams AA, Kechris K, Lutz S, Reisdorph N, Bowler RP. The association of adiponectin with computed tomography phenotypes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:561-566.
11. Suzuki M, Makita H, Östling J, Konno S, Nagai K, Shimizu K, Maciewicz RA, Nishimura M. Elevated plasma adiponectin associated with lung function decline in patients with chronic obstructive pulmonary disease [abstract]. Am J Respir Crit Care Med 2013;187:A3490.
12. Suzuki M, Makita H, Östling J, Thomsen LH, Konno S, Nagai K, Shimizu K, Dirksen A, Maciewicz RA, Nishimura M. Lower plasma leptin/adiponectin ratio predicts lung function decline in patients with chronic obstructive pulmonary disease: An analysis of data from two prospective cohort studies [abstract]. Am J Respir Crit Care Med 2014;189:A5885.
13. Makita H, Nasuhara Y, Nagai K, Ito Y, Hasegawa M, Betsuyaku T, Onodera Y, Hizawa N, Nishimura M; Hokkaido COPD Cohort Study Group. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 2007;62:932-937.
14. Pedersen JH, Ashraf H, Dirksen A, Bach K, Hansen H, Toennesen P, Thorsen H, Brodersen J, Skov BG, Døssing M, et al. The Danish randomized lung cancer CT screening trial-overall design and results of the prevalence round. J Thorac Oncol 2009;4:608-614.
15. Saghir Z, Dirksen A, Ashraf H, Bach KS, Brodersen J, Clementsen PF, Døssing M, Hansen H, Kofoed KF, Larsen KR, et al. CT screening for lung cancer brings forward early disease: The randomised Danish Lung Cancer Screening Trial: Status after five annual screening rounds with low-dose CT. Thorax 2012;67:296-301.
16. Fantuzzi G. Adiponectin in inflammatory and immune-mediated diseases. Cytokine 2013;64:1-10.
17. Summer R, Little FF, Ouchi N, Takemura Y, Aprahamian T, Dwyer D, Fitzsimmons K, Suki B, Parameswaran H, Fine A, et al. Alveolar macrophage activation and an emphysema-like phenotype in adiponectin-deficient mice. Am J Physiol Lung Cell Mol Physiol 2008; 294:L1035-L1042.
18. Nakanishi K, Takeda Y, Tetsumoto S, Iwasaki T, Tsujino K, Kuhara H, Jin Y, Nagatomo I, Kida H, Goya S, et al. Involvement of endothelial apoptosis underlying chronic obstructive pulmonary disease-like phenotype in adiponectin-null mice: implications for therapy. Am J Respir Crit Care Med 2011;183:1164-1175.
19. Miller M, Pham A, Cho JY, Rosenthal P, Broide DH. Adiponectindeficient mice are protected against tobacco-induced inflammation and increased emphysema. Am J Physiol Lung Cell Mol Physiol 2010;299:L834-L842.
20. Miller M, Cho JY, Pham A, Ramsdell J, Broide DH. Adiponectin and functional adiponectin receptor 1 are expressed by airway epithelial cells in chronic obstructive pulmonary disease. J Immunol 2009;182:684-691.
21. Haugen F, Drevon CA. Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology 2007;148: 5478-5486.
22. Cheng X, Folco EJ, Shimizu K, Libby P. Adiponectin induces proinflammatory programs in human macrophages and CD41 T cells. J Biol Chem 2012;287:36896-36904.
23. Hara K, Boutin P, Mori Y, Tobe K, Dina C, Yasuda K, Yamauchi T, Otabe S, Okada T, Eto K, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 2002;51:536-540.
24. Yuan Y, Jiang H, Kuang J, Hou X, Feng Y, Su Z. Genetic variations in ADIPOQ gene are associated with chronic obstructive pulmonary disease. PLoS One 2012;7:e50848.
25. Inoue M, Maehata E, Yano M, Taniyama M, Suzuki S. Correlation between the adiponectin-leptin ratio and parameters of insulin resistance in patients with type 2 diabetes. Metabolism 2005; 54:281-286.
26. Kappelle PJ, Dullaart RP, van Beek AP, Hillege HL, Wolffenbuttel BH. The plasma leptin/adiponectin ratio predicts first cardiovascular event in men: A prospective nested case-control study. Eur J Intern Med 2012;23:755-759.
27. Yoon HI, Li Y, Man SF, Tashkin D, Wise RA, Connett JE, Anthonisen NA, Churg A, Wright JL, Sin DD. The complex relationship of serum adiponectin to COPD outcomes COPD and adiponectin. Chest 2012; 142:893-899.
28. Tantucci C, Modina D. Lung function decline in COPD. Int J Chron Obstruct Pulmon Dis 2012;7:95-99.
29. Pischon T, Hotamisligil GS, Rimm EB. Adiponectin: Stability in plasma over 36 hours and within-person variation over 1 year. Clin Chem 2003;49:650-652.
30. Chu NF, Spiegelman D, Hotamisligil GS, Rifai N, Stampfer M, Rimm EB. Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 2001;157:495-503.
31. Creutzberg EC, Wouters EF, Vanderhoven-Augustin IM, Dentener MA, Schols AM. Disturbances in leptin metabolism are related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;162:1239-1245.
32. Ali Assad N, Sood A. Leptin, adiponectin and pulmonary diseases. Biochimie 2012;94:2180-2189.